Two years previously, TKT signed an exclusive licensing agreement with Genzyme Corporation to market Elaprase (idursulfase), which is a drug used to treat Hunter syndrome (also called MPS-II), in ...

and idursulfase. Sitharaman also announced that 37 more medicines have been added in the list of medicines which when offered to patients through the Patient Assistance Programme (PAP) by global ...

The participants are randomized 2:1 to receive either tividenofusp alfa or idursulfase, respectively. Denali believes that such phenomenal progress in the MPS II program will inform and accelerate ...